Here is a quick recap of trades that we initiated, closed, or debated in the week that was Dec 7th to Dec 11th: Trade Idea – $XLU: Utility Player We continue to think the risk reward …
Continue readingUS
Yesterday in this space I posted a chart of the S&P 500 (SPX) which, without being able to draw an intelligent conclusion, highlighted an occurrence in Wednesday’s trading that had not happened since mid August: Yesterday (Wednesday …
Continue readingCrude Oil remains the headline, now down 11% this month a lone, trading very near 52 week and 7 year lows. Today the commodity opened up 3% after supply data came in weaker than expected, …
Continue reading
I think it’s fair to say that most of the volatility (up and down) in global equity markets over the last twenty years has resulted from investment bubbles created, fueled and then mismanaged by easy monetary policies. That …
Continue readingAirline stocks have been one of the few clear beneficiaries from crude oil’s most recent decline. While the group caught a massive bid today, there is an interesting bifurcation as it relates to year to …
Continue reading
There is little doubt that one of the major contributing factors in crude oil’s 65% decline since mid 2014 has been the US Fed’s wind-down of quantitative easing and the subsequent rally in the US …
Continue reading
On November 6th we placed a trade in the emerging markets etf EEM. Our thinking was that a rising dollar into what looked like a more and more likely December liftoff for the Fed would …
Continue readingThe largest trade (so far) in the options market today is (what appears to be) a fairly massive bearish put spread bought in the iShares Russell 2000 etf, the IWM: When the etf was $119.10, …
Continue reading
On November 6th we placed a defined risk bearish trade in the emerging markets etf EEM. Here were our thoughts at the time and the trade: If you are of the mindset that the fear …
Continue reading
This morning Pfizer (PFE) announced the long rumored buyout/merger agreement with Ireland based maker of Botox, Allergen (AGN), valuing it at $160 billion. While cost cutting and empire building are at the heart of the …
Continue reading